BioCentury | Nov 24, 2014
Clinical News

2MD: Phase IIb data

...weeks led to a 46% reduction in PTH levels vs. a 31% increase for placebo. Deltanoid...
...events reported. Data will be presented at the American Society of Nephrology meeting in Philadelphia. Deltanoid Pharmaceuticals Inc....
BioCentury | Oct 9, 2014
Distillery Therapeutics

Indication: Cancer

...cervical cancers. Teijin Pharma Ltd. markets Bonalfa tacalcitol monohydrate, activated vitamin D3, to treat psoriasis. Deltanoid Pharmaceuticals Inc....
BioCentury | Jan 7, 2008
Strategy

Selling out to reach the finish line

...BioCentury, June 20, 2005 ). The company in-licensed Asord from the University of Wisconsin and Deltanoid Pharmaceuticals Inc....
...in late 2009 or 2010. COMPANIES AND INSTITUTIONS MENTIONED CollaGenix Pharmaceuticals Inc. (NASDAQ:CGPI), Newtown, Penn Deltanoid Pharmaceuticals Inc....
BioCentury | May 21, 2007
Company News

CollaGenex, QuatRx deal

...front and is eligible for undisclosed milestones, plus royalties. QuatRx has rights to becocalcidiol from Deltanoid Pharmaceuticals Inc....
BioCentury | Mar 19, 2007
Clinical News

DP001: Phase II started

...Deltanoid started a U.S. Phase II trial in postmenopausal women. Deltanoid Pharmaceuticals Inc. , Madison, Wis. Product: DP001...
BioCentury | Jun 20, 2005
Clinical News

Becocalcidiol: Phase IIb data

...worldwide marketing and distribution rights to becocalcidiol as a topical treatment for skin disorders from Deltanoid Pharmaceuticals Inc....
BioCentury | Jun 15, 2005
Clinical News

QuatRx becocalcidiol Phase IIb psoriasis data

...worldwide marketing and distribution rights to becocalcidiol as a topical treatment for skin disorders from Deltanoid...
BioCentury | Jul 26, 2004
Company News

Deltanoid, Abbott deal

...renal disease. Deltanoid will receive an upfront fee and is eligible for milestones and royalties. Deltanoid Pharmaceuticals Inc....
BioCentury | Jun 23, 2003
Finance

Measuring runway

...QuatRx $28.0 6/10 Series C Through 3Q05 Psoriasis, lipid disorders Ph II in psoriasis Ilex; Deltanoid...
BioCentury | Jan 20, 2003
Product Development

Deltanoid: Curiously strong

...the disease slow or stop bone loss, but do not promote new bone formation. Thus, Deltanoid Pharmaceuticals Inc....
...preventing bone loss. Pfizer Inc. took an option on 2MD last week, and if exercised, Deltanoid...
...1950s, and this is the only one that targets bone and increases bone formation," said Deltanoid...
Items per page:
1 - 10 of 14
BioCentury | Nov 24, 2014
Clinical News

2MD: Phase IIb data

...weeks led to a 46% reduction in PTH levels vs. a 31% increase for placebo. Deltanoid...
...events reported. Data will be presented at the American Society of Nephrology meeting in Philadelphia. Deltanoid Pharmaceuticals Inc....
BioCentury | Oct 9, 2014
Distillery Therapeutics

Indication: Cancer

...cervical cancers. Teijin Pharma Ltd. markets Bonalfa tacalcitol monohydrate, activated vitamin D3, to treat psoriasis. Deltanoid Pharmaceuticals Inc....
BioCentury | Jan 7, 2008
Strategy

Selling out to reach the finish line

...BioCentury, June 20, 2005 ). The company in-licensed Asord from the University of Wisconsin and Deltanoid Pharmaceuticals Inc....
...in late 2009 or 2010. COMPANIES AND INSTITUTIONS MENTIONED CollaGenix Pharmaceuticals Inc. (NASDAQ:CGPI), Newtown, Penn Deltanoid Pharmaceuticals Inc....
BioCentury | May 21, 2007
Company News

CollaGenex, QuatRx deal

...front and is eligible for undisclosed milestones, plus royalties. QuatRx has rights to becocalcidiol from Deltanoid Pharmaceuticals Inc....
BioCentury | Mar 19, 2007
Clinical News

DP001: Phase II started

...Deltanoid started a U.S. Phase II trial in postmenopausal women. Deltanoid Pharmaceuticals Inc. , Madison, Wis. Product: DP001...
BioCentury | Jun 20, 2005
Clinical News

Becocalcidiol: Phase IIb data

...worldwide marketing and distribution rights to becocalcidiol as a topical treatment for skin disorders from Deltanoid Pharmaceuticals Inc....
BioCentury | Jun 15, 2005
Clinical News

QuatRx becocalcidiol Phase IIb psoriasis data

...worldwide marketing and distribution rights to becocalcidiol as a topical treatment for skin disorders from Deltanoid...
BioCentury | Jul 26, 2004
Company News

Deltanoid, Abbott deal

...renal disease. Deltanoid will receive an upfront fee and is eligible for milestones and royalties. Deltanoid Pharmaceuticals Inc....
BioCentury | Jun 23, 2003
Finance

Measuring runway

...QuatRx $28.0 6/10 Series C Through 3Q05 Psoriasis, lipid disorders Ph II in psoriasis Ilex; Deltanoid...
BioCentury | Jan 20, 2003
Product Development

Deltanoid: Curiously strong

...the disease slow or stop bone loss, but do not promote new bone formation. Thus, Deltanoid Pharmaceuticals Inc....
...preventing bone loss. Pfizer Inc. took an option on 2MD last week, and if exercised, Deltanoid...
...1950s, and this is the only one that targets bone and increases bone formation," said Deltanoid...
Items per page:
1 - 10 of 14